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We enthusiastically read Payandemehr et al.’s 
study, which examined the effect of interferon β-
1a (ReciGen, CinnaGen Co., Iran) on the severity of 
the disease in patients with COVID-19 and 
revealed that taking interferon β-1a (INF) 
significantly reduced the duration of 
hospitalization and the rate of mortality of 
hospitalized COVID-19 patients (1).  
INF is one of the main drugs in patients with 
relapsing-remitting multiple sclerosis (RRMS), 
and these patients mainly use this drug for a long 
time (2). We decided to examine whether the drug 
has an effect on the incidence rate of COVID-19 in 
MS patients and whether it affects the course of 
COVID-19 in case of infection. In November 2020, 
75 RRMS patients treated with INF (ReciGen, 
CinnaGen Co., Iran) were evaluated for COVID-19. 
Fifty-seven and eighteen cases were female and 
male, respectively. Patients had a mean age of 
36.9±7.2 years, disease duration of 7.0±4.4 years, 
and the INF use duration of 3.5±1.7 years. Of these 
75 patients, only one patient (1.33%) tested 
positive for COVID-19. The patient was a 29-year-
old female nurse working in the pediatric 
intensive care unit (ICU) and had been receiving 
INF for six years since the diagnosis of MS. She 
developed symptoms of cough, shortness of 
breath, lethargy, anorexia, constipation, and 
diarrhea in June 2020. The lung computed 
tomography (CT) scan indicated mild lung 
involvement, and the reverse transcription 
polymerase chain reaction (RT-PCR) test was 
positive for COVID-19. The patient continued her 
INF treatment, and the symptoms completely 
disappeared after five days. The patient did not 
require to be hospitalized during her COVID-19 
infection. Therefore, the hospitalization rate due 
to COVID-19, hospitalization in the ICU, and 
mortality rate were zero in INF users. In a study 
by Sahraian et al. (3) addressing 4647 MS patients 
revealed that the incidence of COVID-19 was 
1.46%, which was similar to our findings 
concerning patients receiving INF. However, the 
hospitalization rate in the mentioned study was 
25%, which was very different from that of our 
study. It should be noted that patients were taking 
a wide range of drugs in the mentioned study, and 
most of them were taking rituximab. Nevertheless, 
there was no relationship between the type of the 
administered drug and the chance of 
hospitalization in the mentioned study. Our 
findings suggest that there might be a link 
between the use of INF and non-hospitalization 
and lack of mortality in patients with MS infected 
by COVID-19.  
The obtained findings are in line with the results 
provided by Payandemehr et al.’s study (1). 
Although our study was observational and did not 
have a control group, it revealed that the INF 
administration might reduce the severity of the 
infection. However, the use of INF did not prevent 
COVID-19 infection. The positive effect of 
interferons on reducing the severity of COVID-19 
has been indicated in other studies, as well (4, 5). 
Considering its positive effect on COVID-19 and 
the fact that interferons have been used in the 
treatment of MS disease for many years, more 
attention should be devoted to administering this 
drug in patients with MS during COVID-19 as it 
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